AI Article Synopsis
- Researchers have identified tumor stroma as a key target for anti-cancer therapies, leading to the development of a novel DNA vaccine that targets murine platelet derived growth factor receptor-beta (mPDGFRbeta).
- The vaccine effectively induces immune responses that destroy mPDGFRbeta-expressing cancer cells and prevents the growth of various types of tumors in mice, including colon, breast, and lung carcinomas.
- Additionally, it reduces angiogenesis (the formation of new blood vessels) and decreases the presence of tumor-associated pericytes in the tumor environment, as indicated by lower expression levels of mPDGFRbeta and NG2.
Article Abstract
Over the past several years it has become apparent that the tumor stroma represents a significant target for anti-cancer therapies. Therefore we evaluated the strategy of targeting the tumor stroma with a novel DNA vaccine encoding murine platelet derived growth factor receptor-beta (mPDGFRbeta). Immunization with this vaccine induced cytotoxic lysis of mPDGFRbeta-expressing target cells and protected mice from the growth and dissemination of murine colon, breast and lung carcinoma. Furthermore, this novel vaccine suppresses angiogenesis in vivo and reduces the numbers of tumor-associated, mPDGFRbeta-expressing pericytes as suggested by a decrease in intra-tumoral expression of mPDGFRbeta and NG2.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2006.04.071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!